Stroke Prevention with Factor XIa Inhibition Insights

🧬 Gene-silencing therapies, particularly vutrisiran and patisiran, demonstrate superior efficacy over older pharmacological interventions in improving neuropathy impairment and quality of life in hereditary transthyretin-related amyloidosis with polyneuropathy (ATTRv-PN), although these findings should be regarded as hypothesis-generating given the scarcity of data, lack of head-to-head trials, and clinical heterogeneity across trials. 📚 Read the recently published article "Pharmacological Interventions for Hereditary Transthyretin-Related Amyloidosis With Polyneuropathy: Systematic Review and Network Meta-Analysis" by Duarte et al.: https://buff.ly/3B4ZX1E European Academy of Neurology #WileyNeuro #Amyloidosis #Neuropathy #Neuromuscular #Neurology

𝗙𝗶𝗳𝘁𝗵 𝗘𝗔𝗡 𝟮𝟬𝟮𝟲 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁 𝗻𝗼𝘄 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗼𝗻 𝗠𝗲𝗱𝗶𝗠𝗶𝘅 Prof Dr David Crosiers shares his key takeaways on movement disorders, highlighting how the field is moving towards mechanism-based diagnosis, precision diagnostics and more individualized treatment strategies. This expert-led update covers: - tremor as a network disorder - emerging treatment approaches for essential tremor - neurogenetic advances in rare movement disorders - prodromal Parkinson’s disease and early biomarker detection - developments in DBS and focused ultrasound - diagnostic red flags for rare but potentially treatable conditions 𝗔 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗹𝘆 𝗿𝗲𝗹𝗲𝘃𝗮𝗻𝘁 𝘂𝗽𝗱𝗮𝘁𝗲 𝗳𝗼𝗿 𝗲𝘃𝗲𝗿𝘆𝗼𝗻𝗲 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝘁𝗵𝗲 𝗲𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗺𝗼𝘃𝗲𝗺𝗲𝗻𝘁 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲. For all EAN 2026 videos 👇 find the link in the comments! #MediMix #EAN2026 #EANCongress #Neurology #MovementDisorders #ParkinsonsDisease #Tremor #Dystonia #Neurogenetics #Neuromodulation #MedicalEducation #CongressCoverage

Your AF patient just got a stent. Twelve months of dual therapy — or one? 𝐎𝐏𝐓𝐈𝐌𝐀-𝐀𝐅 (2026, The Lancet) tested exactly that. 𝐖𝐡𝐚𝐭 𝐭𝐡𝐞𝐲 𝐟𝐨𝐮𝐧𝐝: • 1 month of DOAC + P2Y12, then DOAC alone: non-inferior for death or thromboembolism • 𝐌𝐚𝐣𝐨𝐫 𝐨𝐫 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥𝐥𝐲 𝐫𝐞𝐥𝐞𝐯𝐚𝐧𝐭 𝐛𝐥𝐞𝐞𝐝𝐢𝐧𝐠 𝐡𝐚𝐥𝐯𝐞𝐝 (4.5% vs 8.8%) • Efficacy superiority not shown — event rates ran lower than expected 𝐁𝐨𝐭𝐭𝐨𝐦 𝐥𝐢𝐧𝐞: Earlier switch to DOAC monotherapy cuts bleeding without clear loss of protection; interpret efficacy cautiously. How soon do you drop the antiplatelet after PCI in your AF patients? Read the full trial summary on 𝐍𝐞𝐮𝐫𝐨.𝐖𝐢𝐤𝐢: https://lnkd.in/enrE-6MF #NeuroTrials #Neurology #ClinicalTrials #Stroke #StrokeResearch

🎥 𝗡𝗲𝘄 𝗘𝗔𝗡 𝟮𝟬𝟮𝟲 𝗜𝗻 𝗗𝗲𝗽𝘁𝗵 𝘃𝗶𝗱𝗲𝗼 𝗻𝗼𝘄 𝗮𝘃𝗮𝗶𝗹𝗮𝗯𝗹𝗲 𝗼𝗻 𝗠𝗲𝗱𝗶𝗠𝗶𝘅 Prof Dr Richard Nowak, MD, MS discusses updated safety data from the pivotal MINT trial in generalized myasthenia gravis. This expert-led update focuses on adverse events of special interest and further characterizes the safety profile of CD19-targeted B-cell depletion as a mechanism-based therapeutic approach in generalized myasthenia gravis. A clinically relevant update for everyone following the evolving treatment landscape in autoimmune neuromuscular disease. For all EAN 2026 videos 👇 find the link in the comments! #MediMix #EAN2026 #EANCongress #Neurology #MyastheniaGravis #Neuroimmunology #NeuromuscularDisease #AutoimmuneNeurology #MedicalEducation #CongressCoverage

Agile Infusion is pleased to offer UPLIZNA® (inebilizumab-cdon) HCP from Amgen for the treatment of neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody-positive; immunoglobulin G4-related disease in adults; and generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody-positive. To make referrals easier for prescribers, our order form can be found at https://lnkd.in/ejTBqGhn. #UPLIZNA #NMOSD #IgG4RelatedDisease #MyastheniaGravis #RareDisease #Neurology #Rheumatology #InfusionTherapy

Your MS patient keeps progressing on ocrelizumab. Would a higher dose help? 𝐌𝐔𝐒𝐄𝐓𝐓𝐄 & 𝐆𝐀𝐕𝐎𝐓𝐓𝐄 (2026, Lancet) tested exactly that. 𝐖𝐡𝐚𝐭 𝐭𝐡𝐞𝐲 𝐟𝐨𝐮𝐧𝐝: • High-dose ocrelizumab did not slow disability progression better in relapsing MS • 𝐒𝐚𝐦𝐞 𝐫𝐞𝐬𝐮𝐥𝐭 𝐢𝐧 𝐩𝐫𝐢𝐦𝐚𝐫𝐲 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐯𝐞 𝐌𝐒 — 𝐧𝐨 𝐚𝐝𝐝𝐞𝐝 𝐛𝐞𝐧𝐞𝐟𝐢𝐭 𝐨𝐯𝐞𝐫 𝟔𝟎𝟎 𝐦𝐠 • Safety was comparable between doses 𝐁𝐨𝐭𝐭𝐨𝐦 𝐥𝐢𝐧𝐞: Deeper B-cell depletion isn't better. Standard 600 mg remains the right dose. When ocrelizumab patients progress, what's your next move — switch, add, or stay? Read the full trial summary on 𝐍𝐞𝐮𝐫𝐨.𝐖𝐢𝐤𝐢: https://lnkd.in/dsD_QFQg #NeuroTrials #Neurology #ClinicalTrials #MultipleSclerosis #MS

𝐀 𝟕-𝐲𝐞𝐚𝐫-𝐨𝐥𝐝 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐟𝐨𝐨𝐭 𝐝𝐲𝐬𝐭𝐨𝐧𝐢𝐚 𝐚𝐧𝐝 𝐠𝐚𝐢𝐭 𝐝𝐢𝐟𝐟𝐢𝐜𝐮𝐥𝐭𝐲 𝐭𝐡𝐚𝐭 𝐢𝐬 𝐦𝐢𝐥𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐦𝐨𝐫𝐧𝐢𝐧𝐠 𝐛𝐮𝐭 𝐰𝐨𝐫𝐬𝐞𝐧𝐬 𝐝𝐫𝐚𝐦𝐚𝐭𝐢𝐜𝐚𝐥𝐥𝐲 𝐛𝐲 𝐞𝐯𝐞𝐧𝐢𝐧𝐠. 𝐃𝐚𝐓𝐒𝐂𝐀𝐍 𝐢𝐬 𝐧𝐨𝐫𝐦𝐚𝐥. 𝐖𝐡𝐚𝐭 𝐬𝐢𝐧𝐠𝐥𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐭𝐫𝐢𝐚𝐥 𝐦𝐮𝐬𝐭 𝐧𝐨𝐭 𝐛𝐞 𝐦𝐢𝐬𝐬𝐞𝐝? • Dystonia is classified by body distribution: focal, segmental, multifocal, generalized, and hemidystonia • Treatment tracks with distribution — botulinum toxin for focal, trihexyphenidyl and GPi DBS for generalized (DYT-TOR1A is the best DBS responder) • Two diagnoses you can never miss in young-onset dystonia: dopa-responsive dystonia (trial levodopa) and Wilson disease 💬 Which dystonia case has tripped you up most on the wards — the diurnal-fluctuation kid, the drug-induced oculogyric crisis, or the adult hemidystonia hiding a stroke? Full reference on 𝐍𝐞𝐮𝐫𝐨.𝐖𝐢𝐤𝐢: https://lnkd.in/euFcZbfP #NeuroWiki #Neurology #MedEd #ClinicalPearls #Parkinsons #MovementDisorders #DBS

Autoimmune encephalitis has moved past the diagnostic era — antibody testing is no longer the bottleneck. New data presented at AAN Autoimmune Neurology 2026 show cumulative relapse burden independently predicts poor long-term functional and cognitive outcomes in LGI1-AE (OR 2.94), while rituximab significantly reduces relapse risk (HR 0.19). Meanwhile, the COAST study documents wide practice variation in second-line NMDAR-AE therapy — rituximab (60.3%), cyclophosphamide (13.5%), tocilizumab (4.0%) — with no consensus on regimen or duration. A new patient-reported outcome measure, LANTERN, may finally capture what conventional scales miss: the executive dysfunction and psychiatric burden that persist even when clinician-rated outcomes look “good.” Full clinical breakdown of the AANAI 2026 encephalitis data: https://lnkd.in/ejqb3yQv #AutoimmuneNeurology #AANAI2026 #Neurology #Encephalitis #MedEd

Vestibular Paroxysmia is an uncommon but important cause of recurrent episodic vertigo that is frequently overlooked or misdiagnosed as BPPV, vestibular migraine, or Ménière disease. Recognising its characteristic pattern of very brief, frequent, stereotyped attacks, often accompanied by transient unilateral auditory symptoms and a striking response to sodium-channel blockers, can prevent years of diagnostic uncertainty and unnecessary treatment. This infographic reviews the current understanding of pathophysiology, Bárány Society diagnostic criteria, differential diagnosis, imaging considerations, and evidence-based management. While MRI may demonstrate an AICA vascular loop contacting the vestibulocochlear nerve, imaging findings must always be interpreted in the appropriate clinical context, as neurovascular contact alone does not establish the diagnosis. I hope this visual summary serves as a practical bedside reference for residents, neurologists, ENT specialists, and physicians involved in the evaluation of patients with recurrent vertigo. #Neurology #NeuroOtology #VestibularParoxysmia #Vertigo #Dizziness #VestibularDisorders #ClinicalNeurology #MedicalEducation #NeurologyResident #ENT #Neuroimaging #EvidenceBasedMedicine

🧠 📣 Throughout the month, NeurologyLive will be covering spinal muscular atrophy (SMA), a rare genetic neuromuscular disorder, with a focus on the multidisciplinary care approach and the many clinicians who make it work.   📚 First up! A literature review of 5 recent studies on multidisciplinary care in SMA spanning: 💠 Newborn screening pathways 💠 Rehabilitation management 💠 Swallowing and feeding outcomes 💠 Integrated care delivery 💠 Transition to adult services To learn more, click here 👉 https://hubs.ly/Q04s0nHn0 #SMA #SpinalMuscularAtrophy #Neurology #Neuromuscular #RareDisease Cure SMA